Jakseas 5mg Tablet contains Tofacitinib, a Janus kinase (JAK) inhibitor used primarily for the treatment of autoimmune conditions. Tofacitinib modulates the immune response by selectively inhibiting JAK enzymes, which play a critical role in the signaling pathways involved in inflammation and immune cell function. This medication is indicated for the management of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adult patients who have had an inadequate response or intolerance to conventional therapies. Jakseas 5mg Tablet helps reduce symptoms such as joint pain, swelling, and stiffness, thereby improving physical function and quality of life. It is administered orally, with dosage tailored according to the specific condition and patient response. Common adverse effects include upper respiratory tract infections, headache, and gastrointestinal disturbances. Serious risks involve increased susceptibility to infections, malignancies, and potential blood abnormalities; therefore, regular monitoring of blood counts, liver function, and lipid profiles is essential during therapy. Jakseas should be used cautiously in patients with a history of chronic infections or immunodeficiency. It is contraindicated in patients with active infections and should not be combined with other immunosuppressive agents without medical supervision. Always consult a healthcare professional before initiating or discontinuing treatment.